No Data
No Data
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
Optimistic Outlook on Beam Therapeutics: Advancements and Potential in Precision Genetic Medicines
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine With CRISPR Technology
Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)
Beam Therapeutics: Hold Rating With Stable Financial Outlook Amid Clinical Pipeline Progress and Upcoming Data Releases